Chemo, Immunotherapy Combo May Help Fight Liver Cancer, Study Says
Combining the chemotherapy agent Sutent (sunitinib) and immunotherapy may be a promising strategy to fight hepatocellular carcinoma, the most common type of liver cancer, according…
Liver cancer
Tivantinib Provides No Survival Benefit in Hepatocellular Carcinoma Patients, Phase 3 Study Shows
Tivantinib, an experimental oral inhibitor of the MET receptor, is not better than best supportive care in patients with inoperable hepatocellular carcinoma (HCC) who are intolerant or…
Recent Posts
- Maralixibat reduces itch in children with biliary atresia: Case series
- Phase 3 trials of treatment combo for hepatitis D expected in 2025
- Doing our part to hasten a cure for our daughter’s PFIC3
- PBC treatment Livdelzi shows benefits for 2.5 years in Phase 3 trial
- Bylvay eases itch over long term in PFIC, Alagille syndrome patients